1. Introduction

Bioprinted tissue ownership disputes are an emerging area of biotechnology law involving the legal rights over human tissues, organs, cellular materials, and biological structures manufactured through three-dimensional (3D) bioprinting technologies.

In Russia, this subject intersects several branches of law:

Constitutional law and protection of human dignity.

Civil law and ownership of biological materials.

Medical law and informed consent.

Intellectual property law and biotechnology patents.

Personal data and genetic information protection.

Contract law governing research institutions, hospitals, and biotechnology companies.

Criminal and administrative liability for unlawful handling of human biological materials.

The central legal question is: Who has legal rights over bioprinted tissue when it is created using cells obtained from a human donor, developed through a university research programme, and manufactured using a private biotechnology company's technology?

A donor, research institution, biotechnology company, and medical institution may all have competing interests. Russian law does not yet provide a comprehensive, standalone ownership regime specifically for bioprinted human tissues. Consequently, existing constitutional, civil, medical, patent, and personal-data rules must be considered together.

2. Russian Legal Framework Governing Bioprinted Tissue

A. Federal Law No. 323-FZ of 21 November 2011 – Protection of Citizens' Health

This is one of the principal laws governing medical activities, human tissues, medical consent, and transplantation in Russia.

Article 47 addresses:

Donation of human organs and tissues.

Informed voluntary consent of living donors.

Medical conditions for tissue removal.

Consent of recipients to transplantation.

Restrictions on the removal of organs and tissues from deceased persons.

Article 68 regulates the use of deceased persons' bodies, organs, and tissues for medical, scientific, and educational purposes.

Relevance to bioprinted tissue ownership: If a laboratory obtains human cells or tissues for bioprinting, the lawful collection and intended use of those materials become important. Consent for collecting biological material should not automatically be treated as unlimited permission to commercialise every subsequent product.

minzdrav.gov.ru+1

B. Law No. 4180-I of 22 December 1992 – Transplantation of Human Organs and Tissues

This legislation establishes the legal framework for human organ and tissue transplantation.

Its important principles include:

Human organs and tissues cannot generally be objects of purchase and sale.

Living-donor tissue removal requires legally valid consent and compliance with medical safeguards.

Medical institutions must respect donor and recipient rights.

Violations may result in legal liability.

Article 15 prohibits authorised medical organisations from selling organs and tissues obtained from deceased persons. However, the law excludes certain preparations and transplant materials made using tissue components.

Ownership implication: A dispute may arise over whether a bioprinted construct is legally a human tissue, a tissue-derived preparation, or an independently manufactured biomedical product. Its classification can determine whether the statutory prohibition on sale applies.

Importantly, it would be incorrect to assume that every commercially manufactured bioprinted product is automatically prohibited from sale under this legislation.

Consultant Plus+2

C. Federal Law No. 180-FZ of 23 June 2016 – Biomedical Cellular Products

This law regulates the development, testing, registration, manufacture, quality control, storage, transportation, and use of biomedical cellular products.

It also addresses the donation of biological material for manufacturing such products.

It is particularly relevant where bioprinting involves:

Cultured human cells.

Cellular therapeutic products.

Regenerative medicine.

Tissue-engineered materials.

Personalised cellular treatments.

However, the existence of this regulatory framework does not mean that every 3D-bioprinted tissue is automatically classified as a biomedical cellular product.

The legal classification depends on the nature, composition, intended purpose, and regulatory characteristics of the product.

CIS Legislation+1

D. Russian Civil Code – Property and Intellectual Property Rights

The Civil Code provides the general legal framework for determining contractual rights, ownership, intellectual property, and liability.

Particularly relevant provisions include:

Article 209 – Powers of an owner.

Article 218 – Grounds for acquiring ownership.

Article 1228 – Authorship of intellectual property.

Article 1350 – Patentability requirements.

Article 1357 – Right to obtain a patent.

Article 1350 recognises qualifying technical solutions relating to products and processes as potentially patentable inventions.

Therefore, a biotechnology company may potentially protect:

A new bioprinting technique.

A specialised bioink formulation.

A technical manufacturing process.

A qualifying engineered cellular construct.

Nevertheless, patent protection over a technical invention does not automatically establish ownership of the human cells used in its development.

rospatent.gov.ru+2

3. Meaning of Ownership in Bioprinted Tissue Disputes

A major difficulty is that the word ownership may describe several legally different interests.

A court should not automatically treat all these interests as one indivisible ownership right.

4. Major Categories of Bioprinted Tissue Ownership Disputes

A. Donor Versus Biotechnology Company

Suppose a Russian biotechnology company obtains a patient's skin cells and uses them to manufacture artificial skin tissue.

The company subsequently commercialises the resulting technology.

The donor may argue that:

The cells were provided only for medical treatment.

The company exceeded the scope of consent.

The material was used for unauthorised research.

The company commercially exploited biological material without contractual authorisation.

The company may argue that:

It lawfully obtained the cells.

It independently developed the manufacturing process.

The resulting construct is a manufactured biomedical product.

Its intellectual property rights protect the technical innovation.

Legal analysis: The decisive questions include the donor's consent, the contractual terms, the product's classification, and the distinction between biological material and the resulting technical invention.

B. Patient Versus Hospital

A patient may provide cells to a hospital for the production of personalised tissue.

After treatment, the hospital retains unused cells or manufactured tissue for further research.

The patient may object to continued storage or research use.

Relevant issues include:

Scope of informed consent.

Confidentiality of medical information.

Secondary research use.

Retention and destruction of biological material.

Contractual obligations of the medical institution.

The hospital cannot simply assume that permission for treatment authorises every subsequent research use.

C. University Versus Researcher

A university researcher develops a novel bioprinted tissue using university equipment and laboratory facilities.

The researcher claims personal ownership of the invention, whereas the university claims employment-related intellectual property rights.

Article 1228 of the Civil Code distinguishes the actual author from persons who provide only organisational, technical, or financial assistance.

The ownership of exclusive rights must also be examined under the Civil Code's rules governing employee-created inventions and contractual arrangements.

D. Two Biotechnology Companies

Company A develops a specialised bioink, while Company B uses that formulation to produce bioprinted cartilage.

A dispute may arise over:

Patent infringement.

Trade-secret misuse.

Contractual restrictions.

Manufacturing rights.

Ownership of improvements.

Licensing and commercial distribution.

These disputes are principally intellectual-property and commercial-contract disputes rather than disputes over the donor's ownership of human tissue.

5. Important Case Laws and Judicial Principles

Important distinction

There is no established body of published Russian judicial decisions specifically determining ownership of 3D-bioprinted human tissue. The following decisions and judicial materials are relevant by analogy. They should not be represented as direct bioprinted-tissue ownership precedents.

Case 1. Constitutional Court of the Russian Federation – Decision No. 459-O of 4 December 2003

Определение Конституционного Суда РФ от 04.12.2003 № 459-О

Relevant constitutional and transplantation precedent

The Constitutional Court considered a request concerning the constitutionality of Article 8 of the Russian transplantation legislation.

The decision discussed the legal safeguards governing the removal of organs and tissues from deceased persons.

The Court referred to the principle that human interests must prevail over the interests of society and science.

It also addressed the prohibition on removal when the medical institution has been informed of a legally relevant objection to donation.

Relevance to bioprinting:

This decision provides an important interpretative principle: scientific advancement does not automatically override legally protected human interests.

If a laboratory obtains biological material in violation of applicable consent requirements, subsequent technological processing does not necessarily eliminate the original legal violation.

Consultant Plus

Case 2. Russian Court – Case No. 2-156/2017

Decision dated 2 April 2017

This case concerned the statutory requirements governing the removal and transplantation of organs and tissues from living donors.

The judicial discussion addressed:

Medical examination of the donor.

Voluntary and informed consent.

Medical justification for removal.

Restrictions on commercial transactions involving human organs and tissues.

Relevance to bioprinting:

The case illustrates the importance of distinguishing between lawful donation and commercial acquisition of human biological materials.

A biotechnology company cannot assume that a commercial agreement automatically overrides statutory donor protections.

However, the decision concerns transplantation legislation, not ownership of 3D-printed tissue.

Sudact+1

Case 3. First Cassation Court of General Jurisdiction – Case No. 8G-34785/2024 (88-38716/2024)

Civil cassation decision dated 16 December 2024

This case concerned the use of donor biological material in assisted reproductive technology.

The dispute involved the destruction of a patient's medical record and the question of whether the available evidence established the patient's awareness and consent to the use of donor material.

The court considered the totality of the available evidence, including the parties' conduct and medical circumstances.

Relevance to bioprinted tissue:

This decision is useful for understanding evidentiary disputes involving biological material.

In a bioprinting dispute, courts may similarly need to examine:

Written consent forms.

Medical records.

Laboratory records.

Research agreements.

Material-transfer agreements.

Evidence concerning the intended use of donor cells.

The decision does not establish a property right in donor cells or bioprinted tissues.

ГАРАНТ

Case 4. Moore v. Regents of the University of California (1990) – Comparative Case

California Supreme Court, United States, 793 P.2d 479

This is not a Russian judgment, but it is an important comparative authority in disputes involving human biological materials.

The case concerned a patient's cells that were used to develop a commercially valuable cell line without his knowledge of the researchers' economic interests.

The court rejected the patient's conversion claim concerning the excised cells but recognised that failure to disclose relevant financial interests could support a claim for breach of informed-consent and fiduciary duties.

Relevance to Russia:

The case provides a useful comparative framework for distinguishing:

Rights concerning the original biological material.

Rights concerning research and scientific inventions.

Rights concerning commercial exploitation.

Duties to disclose the intended use of biological samples.

It is persuasive academic material, not binding Russian law.

6. Commercialisation of Bioprinted Tissues in Russia

Commercialisation creates some of the most difficult ownership questions.

Consider a company that manufactures artificial cartilage using human-derived cells and a proprietary 3D-printing process.

Three different legal interests may arise:

1. Biological-material interests

The company must establish the lawful acquisition and permitted use of the original biological material.

2. Intellectual-property interests

The company may seek patent protection for qualifying manufacturing methods, bioink compositions, or technical inventions.

3. Product-related contractual interests

The company and hospital may determine responsibility for manufacturing, storage, delivery, payment, and use through appropriate contracts.

Russian law must distinguish the commercialisation of a technical product from prohibited transactions involving human organs and tissues.

Article 15 of Law No. 4180-I is particularly important because it expressly prohibits certain sales while excluding specified tissue-derived preparations and transplant materials.

Consultant Plus+2

7. Privacy and Genetic Information Ownership

Bioprinted tissues may contain identifiable genetic information.

For example, a laboratory may use a patient's stem cells to create artificial skin or cartilage.

Even after the tissue has been manufactured, information about its biological origin may remain identifiable.

Relevant legislation includes:

Federal Law No. 152-FZ of 27 July 2006 on Personal Data.

Federal Law No. 323-FZ on the protection of citizens' health.

Federal Law No. 180-FZ on biomedical cellular products.

Potential disputes include:

Unauthorised genetic analysis.

Disclosure of donor identity.

Commercial use of identifiable biological information.

Transfer of biological samples to third parties.

Research conducted beyond the scope of consent.

An important distinction is that ownership of a physical sample, rights over personal data, and control over medical information are separate legal questions.

8. Contractual Disputes Concerning Bioprinted Tissue

Contracts are particularly important because Russian legislation does not establish a complete ownership regime specifically for bioprinted tissues.

The following contractual arrangements may be relevant:

A well-drafted agreement should expressly address ownership or control of remaining samples, secondary research, commercialisation, publication, intellectual property, storage, destruction, and liability.

9. Liability for Unlawful Bioprinted Tissue Ownership Claims

Different forms of liability may arise depending on the conduct.

Civil liability

Under the Civil Code, affected parties may pursue remedies where contractual obligations, property interests, personal rights, or legally protected interests have been violated.

Potential remedies include:

Compensation for proven losses.

Compensation for non-pecuniary harm where legally available.

Injunctions against unlawful conduct.

Contractual remedies.

Protection of intellectual property rights.

Administrative liability

Administrative sanctions may arise from violations of applicable medical, sanitary, licensing, and personal-data requirements.

Criminal liability

Where the facts satisfy the relevant statutory elements, criminal liability may arise from unlawful conduct involving human organs or tissues, coercive removal, fraud, or other offences.

Importantly, merely manufacturing or selling a bioprinted construct does not automatically constitute a criminal offence. Its legal classification and the precise conduct must be examined.

10. Major Unresolved Legal Issues in Russia

Several questions remain particularly important for future legislation and judicial interpretation.

A particularly important distinction concerns the legal transformation of biological material.

The fact that a construct has undergone extensive technological processing does not automatically establish that all donor-related rights and restrictions have disappeared.

11. Recommendations for Legal Reform in Russia

Russia could develop a dedicated legal framework addressing the following matters:

1. Bioprinted tissue classification: Define artificial tissues, cellular constructs, bioinks, and tissue-engineered products.

2. Donor protection: Establish clear rules concerning informed consent and the secondary use of donated biological materials.

3. Ownership and control: Distinguish ownership of equipment, manufacturing technology, biological materials, and resulting constructs.

4. Commercialisation: Clarify which products may be commercially manufactured, transferred, and distributed.

5. Research agreements: Establish standard requirements for biological-material transfer and collaborative research.

6. Patient rights: Protect patient interests concerning personalised bioprinted tissues.

7. Intellectual property: Clarify patentability and ownership of inventions arising from collaborative bioprinting research.

8. Dispute resolution: Establish specialist procedures for resolving disputes involving biotechnology companies, hospitals, donors, and researchers.

12. Conclusion

Bioprinted Tissue Ownership Disputes in Russia represent an emerging legal challenge involving human dignity, donor consent, biotechnology innovation, medical regulation, and intellectual property.

The existing legal framework provides several relevant protections through Federal Law No. 323-FZ, Law No. 4180-I, Federal Law No. 180-FZ, and the Russian Civil Code.

However, these laws do not collectively establish a comprehensive and definitive ownership regime for every category of bioprinted human tissue.

The most important legal distinction is between the original human biological material, the technology used to process it, and the resulting bioprinted construct.

A donor's biological contribution does not automatically confer ownership of every subsequent invention. Equally, a company's investment in bioprinting technology does not automatically eliminate the donor's legally protected interests.

Future Russian legislation will need to reconcile these competing interests while ensuring that biotechnology innovation remains consistent with human dignity, informed consent, and medical ethics.

13. Important Legal References and Research Sources

Federal Law No. 323-FZ – Protection of Citizens' Health.

Law No. 4180-I – Human Organ and Tissue Transplantation.

Federal Law No. 180-FZ – Biomedical Cellular Products.

Civil Code of the Russian Federation.

Constitutional Court Decision No. 459-O (2003).

Bioethical and Legal Issues in 3D Bioprinting.

Legal Regulation of Bioprinting Products, Human Organs and Tissues – Russian legal research.

Academic research qualification: The direct judicial authorities discussed above concern transplantation and assisted reproduction, not disputes over ownership of 3D-bioprinted tissues. The legal conclusions concerning bioprinted constructs are therefore reasoned applications of existing Russian law, not established judicial holdings.

I can also develop the next topic, Bioprinted Organ Intellectual Property Disputes in Russia – Detailed Explanation With Case Laws, using the same legal-research structure.